Alchemist Limited Overview
| Field | Detail | Source |
|---|---|---|
| Legal name | Alchemist Limited | BSE / IBBI records |
| Corporate Identification Number (CIN) | L72200DL1988PLC192643 | IBBI public announcement |
| Former names | Toubro Industries Ltd → Toubro Infotech & Industries Ltd (renamed 2000) → Alchemist Limited (w.e.f. 29 Dec 2004). Note: CRISIL describes the original name as "Toubro Infotech & Industries Ltd"; Wikipedia describes the group's predecessor as "Turbo Industries." Discrepancy flagged. | IIFL company summary; CRISIL rationale Nov 2025; Wikipedia (K.D. Singh) |
| Founding / incorporation | Incorporated 5 July 1988 (CIN and BFSL data). IIFL states 1981; CRISIL states 1988. The 1988 date is consistent with the CIN and is treated as authoritative. | BFSL/Vogue data; CRISIL; IIFL |
| Founder | Dr Kanwar Deep Singh ("K.D. Singh"), former Rajya Sabha MP | CRISIL; Wikipedia |
| Incorporation jurisdiction | National Capital Territory of Delhi, India (Companies Act) | CIN prefix "DL" |
| Headquarters / registered office | Alchemist House, Building No. 23, Nehru Place, New Delhi 110019, India. Tel +91 11 4060 0800 | Yahoo Finance profile; BFSL |
| Stock exchanges and tickers | NSE: ALCHEM (series BZ); BSE: 526707. MCX-SX also listed historically. | Screener.in; BFSL |
| ISIN | INE964B01033 | NSE press release 27 Jul 2007; Business Standard |
| CUSIP | Not applicable (no US listing) | — |
| Face value | ₹10 per share (consolidated from ₹1 to ₹10 effective 31 Jul 2007) | NSE press release 27 Jul 2007 |
| Shares outstanding (derived) | Approximately 1.36 crore (13.6 million) shares, derived from equity capital of ~₹14 Cr at ₹10 face value and from FY2020 EPS of -₹34.46 on a net loss of ₹47 Cr | Derived from Screener.in |
| Fiscal year end | 31 March | Annual reports |
| Registrar & transfer agent | MUFG Intime India Pvt Ltd (formerly Link Intime), New Delhi | BFSL |
| Employees (latest) | 189 full-time (date of data point not specified by aggregator; likely FY2020) | Yahoo Finance; MarketScreener |
| Employee 3-year trend | Not publicly disclosed in sources reviewed. Insolvency claims list (Jul 2022) shows 60 employee claims totalling ₹3.70 Cr, indicating unpaid staff dues. | IBBI list of creditors 29 Jul 2022 |
| Auditor | — | — |
| Market capitalisation | ₹4.08 Cr at last traded price of ₹3.01 (13 Dec 2021); free-float market cap ₹2.66 Cr. No live market price exists. | BSE quote page; Screener.in |
| Book value per share | -₹283 (negative; Sep 2020 balance sheet) | Screener.in |
| Credit rating | CRISIL D (Issuer Not Cooperating), reaffirmed 27 Nov 2025, on ₹32.5 Cr bank facilities | CRISIL rationale |
| Insolvency status | CIRP admitted 30 Nov 2021 (IB-275/ND/2020); recalled by NCLT New Delhi Bench IV on 3 Feb 2026; moratorium lifted; RP appointment nullified | IBBI order register; Moneylife; LiveLaw |
| Listing status | Trading suspended; BSE quote page flags suspension due to non-payment of annual listing fee (ALF) dues | BSE |
| Website | http://www.alchemist.co.in | Company |
| Investor email | investors@alchemist.co.in | BFSL |
The entity profiled is the listed company identified by the user's details. Name, ticker and website are unchanged; the listing has not moved, but trading is suspended.
Alchemist Limited is the original listed flagship of the Delhi-headquartered Alchemist Group founded by K.D. Singh. Once a diversified mid-cap trading and agri-processing company with peak standalone revenue of ₹827 Cr (FY2014), it described itself in its final reporting years as engaged in agriculture and allied activities (floriculture), manufacture of welded wire mesh for the poultry industry, and trading of chemicals and pharmaceutical formulations, operating plants at Solan and Sirmour (Himachal Pradesh) and Ropar (Punjab). Since FY2015 the company has been economically inert: revenue collapsed to ₹14 Cr by FY2020, net worth turned deeply negative, borrowings of roughly ₹764–767 Cr remain unserviced, and ~₹475 Cr of receivables appear to have been written down in Q2 FY2021. Today the company's value proposition is entirely legal and forensic: its fate turns on PMLA attachment, investor-restitution litigation in the Calcutta High Court, and the aftermath of a CIRP the NCLT found fraudulent.
Company's own description
In its last annual reports and as reflected in exchange and data-vendor profiles derived from them, Alchemist Limited describes itself as being "engaged in the business of agriculture and allied activities comprising of floriculture and manufacturing of wire mesh for poultry industry and trading of chemicals and pharmaceutical formulations" (Screener.in company summary, sourced from FY2020 annual report). Data vendors drawing on the same filings state that the company reports two segments — Agri Business and Pharma, Chemical & Minerals — with a pharma unit at Solan (Himachal Pradesh), a steel/wire unit at Ropar (Punjab), a floriculture unit at Sirmour (Himachal Pradesh), and a subsidiary named Alchemist Healthcare Limited (MarketScreener profile).
Older company descriptions (IIFL summary) present a much broader conglomerate scope — steel, floriculture, pharma, hospitality, real estate, information technology, food processing, healthcare and international business — reflecting the pre-2015 era when the listed company sat at the centre of group activity. CRISIL's 2025 rationale describes the company as a diversified corporation with operations in chemical trading, pharmaceuticals, food-processing, floriculture, and steel.
Independent characterisation
The financial record supports a sharper characterisation. Between FY2009 and FY2014, revenue grew from ₹386 Cr to ₹827 Cr while operating margins compressed from 8% to 1.5% — the profile of a low-margin trading business (chemicals, minerals and similar commodities) layered on top of small manufacturing assets. In FY2014, borrowings jumped from ₹302 Cr to ₹773 Cr and "other assets" (predominantly receivables) from ₹153 Cr to ₹714 Cr, with operating cash flow of -₹255 Cr funded by +₹431 Cr of financing inflows. Revenue then fell to ₹252 Cr in FY2015 and ₹19 Cr in FY2016, while debtor days exploded from 168 (FY2014) to 9,151 (FY2016). In plain terms, the company borrowed heavily, booked trading sales on credit, and those receivables were never collected.
From FY2016 to FY2020 the residual operating business — wire mesh, floriculture and pharmaceutical formulation trading — generated ₹14–27 Cr of annual revenue at deeply negative operating margins (-36% to -354%). The September 2020 quarter recorded expenses of ₹373 Cr against revenue of ~₹1 Cr, most plausibly a write-off of the legacy receivables, partly offset by ₹124 Cr of other income (most plausibly a write-back of liabilities; "other liabilities" fell from ₹161 Cr to ₹42 Cr in the same period). The company is best characterised today as a legacy shell holding impaired assets, ~₹764 Cr of debt, and contested claims, embedded in a group under criminal investigation.
Business and revenue model
| Dimension | Characterisation (last reported period, FY2020 / H1 FY2021) |
|---|---|
| Revenue model | Product sales (wire mesh, flowers) and traded goods (pharma formulations, chemicals). No subscription, licensing or service revenue disclosed. |
| Product vs. service mix | Effectively 100% product/trading; split not publicly disclosed in sources reviewed |
| Value-chain position | Small-scale downstream manufacturer (wire drawing/mesh welding; cut-flower cultivation) and distributor/trader (pharma formulations, chemicals) |
| Customer types | Poultry farms and fencing buyers (wire mesh); flower wholesalers; pharmacies/distributors (formulations); industrial buyers (chemicals) |
| End-markets | Indian poultry and construction/fencing; domestic floriculture; domestic pharmaceutical retail |
| Scale | FY2020 revenue ₹14 Cr; TTM to Sep 2020 ₹6 Cr |
| Current operating status | Not publicly disclosed; no filings after Q2 FY2021. CIRP-era disclosures and the RP's management of assets (Dec 2021–Feb 2026) suggest minimal or no operations. |
Strategy
The company has published no strategy statement, investor presentation, investor day, medium-term targets or guidance since at least FY2020. The FY2020 annual report's description focuses on maintaining the agri (floriculture, wire mesh) and pharma/chemical trading activities; no transformation programme, ESG commitment or cost-reduction target is publicly disclosed.
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026): none announced by the company. The only "strategic" developments are legal:
Management medium-term financial targets: not publicly disclosed.
Products & Services
Agri Business
| Product line | Description and capabilities | Target customer | Launch / latest year | Pricing model | Source |
|---|---|---|---|---|---|
| Welded wire mesh ("Alchemist Steel") | Welded wire mesh manufactured in 100 grades at Ropar, Punjab | Poultry farms (cages, enclosures), construction | Operational through FY2020; launch year not disclosed | — | IIFL; MarketScreener |
| Steel wires for barbed and razor wire | Wire used by fabricators to make barbed and razor wire | Fencing fabricators | — | — | Yahoo Finance profile |
| Chain-link and other wire fencing | Fencing products for poultry and for residential/non-residential buildings | Poultry, real estate, institutional buyers | — | — | Yahoo Finance profile |
| Floriculture | Cut-flower cultivation at Sirmour, HP; a solar energy device was developed for the floriculture unit in FY1995 | Flower wholesalers, domestic/export markets | Unit dates to the 1990s | — | IIFL; MarketScreener |
Pharma, Chemical & Minerals
| Brand / line | Description / indication | Target customer | Year | Pricing | Source |
|---|---|---|---|---|---|
| Anemi-XT | Formulation for iron deficiency | Prescribers, pharmacies | — | — | FMP / MarketScreener |
| Valcal-M | Formulation for calcium deficiency | Prescribers, pharmacies | — | — | FMP / MarketScreener |
| IGTG Forte | Formulation marketed for weak immunity | Prescribers, pharmacies | — | — | FMP / MarketScreener |
| Gasease | Gastrointestinal formulation | Prescribers, pharmacies | — | — | MarketScreener |
| Wider therapy portfolio | Immune enhancers, nutraceuticals, antibacterials, gastrointestinals, pain relievers, anti-allergics, anti-cold, steroids, enzymes, supplements, CNS | Domestic pharma retail | — | — | FMP / MarketScreener |
| Chemicals and minerals trading | Trading of chemicals and minerals; historically the bulk of revenue (inferred from FY2009–FY2014 margin profile) | Industrial buyers | — | — | Screener.in; CRISIL |
Discontinued / historical lines
| Line | Description | Period | Source |
|---|---|---|---|
| Chicken processing | Plant with 4,000 birds/hour capacity | Commissioned FY2000 | IIFL |
| Republic of Chicken (retail) | Branded retail stores in Delhi | From FY2008 | IIFL |
| Republic of Chicken (restaurants) | National restaurant chain build-out (via Alchemist Foods) | From FY2009 | IIFL |
| Hospitality, real estate, IT, healthcare | Listed in older company summaries as business areas | Pre-2015 | IIFL |
Financial Narrative
Basis: Standalone, ₹ Cr, as compiled by Screener.in from audited annual reports FY2016–FY2020 (BSE). Figures are rounded to the nearest crore by the source; ratios computed from rounded figures carry rounding error. No audited financials have been published for FY2021 or later; H1 FY2021 (to 30 Sep 2020) is shown separately.
Income statement
Gross profit and diluted EPS are not separately disclosed in the compiled data; there are no dilutive instruments disclosed, so diluted EPS is presumed equal to basic.
Margins and growth
Revenue CAGR FY2016–FY2020: -7.4% (₹19 Cr to ₹14 Cr). Screener.in reports 5-year compounded sales growth of -44%, 10-year of -28% and 3-year of -15% (measured to TTM Sep 2020).
Interim: H1 FY2021 (last published results)
TTM to Sep 2020: revenue ₹6 Cr; net loss ₹228 Cr; EPS -₹168.41. Business Standard reports a consolidated Q2 FY2021 loss of ₹185.62 Cr on total income of ₹124.86 Cr, consistent with the standalone data.
Balance sheet
Sep 2020 half-year balance sheet: reserves -₹397 Cr; borrowings ₹764 Cr; other liabilities ₹42 Cr; total assets ₹422 Cr; other assets ₹116 Cr.
Not publicly disclosed in compiled data: cash and equivalents separately; short-term vs long-term debt split; goodwill and intangibles; working capital. Insolvency claims provide a cross-check on debt: financial creditor claims admitted totalled ₹914.92 Cr (19 Jan 2022, then classed as secured, 3 claims) and ₹919.49 Cr (29 Jul 2022, reclassified as unsecured, 5 claims) — higher than book borrowings, likely reflecting accrued interest. This classification shift between lists is itself a discrepancy worth noting.
Cash flow
Capex is not separately disclosed in compiled data; the gap between CFO and FCF implies negligible net capex (FY2017 and FY2018 FCF exceed CFO, implying small net asset-disposal inflows of ~₹5 Cr and ~₹1 Cr).
Ratios
NM = not meaningful (negative equity or negative EBITDA). Net debt/EBITDA is not meaningful in every year (negative EBITDA). Current ratio and ROIC are not publicly disclosed in compiled data; ROCE is the closest proxy. Screener.in flags contingent liabilities of ₹315 Cr.
Commentary
Revenue. The defining inflection is FY2015: revenue fell 70% to ₹252 Cr, then 92% to ₹19 Cr in FY2016. The FY2009–FY2014 revenue growth (CAGR ~16%) came with continuously declining margins, a pattern consistent with volume-driven commodity trading rather than value-added manufacturing. Once trading stopped — coinciding with the period in which SEBI and later the ED began scrutinising the group's fund flows — the residual business was tiny.
Profitability. Every year since FY2015 has been loss-making. FY2017's ₹107 Cr loss was driven by negative other income of ₹69 Cr; investments fell by ₹73 Cr that year (₹244 Cr to ₹171 Cr), indicating an impairment of investments booked through other income. FY2019 and FY2020 losses of ₹50 Cr and ₹47 Cr were driven by expenses far exceeding revenue (₹80 Cr and ₹65 Cr), likely including provisions against receivables.
Balance sheet. Net worth went from ₹25 Cr (FY2016) to -₹196 Cr (FY2020) and -₹383 Cr (Sep 2020; equity ₹14 Cr plus reserves -₹397 Cr). Borrowings have been essentially static at ₹727–767 Cr for six years, meaning interest is either not being accrued in the P&L at contractual rates (interest expense of just ₹1–3 Cr on ~₹750 Cr of debt implies an effective rate below 0.5%) or debts are owed to parties not charging interest. This is a major red flag: either the debt is owed largely to related parties, or interest is not being recognised. The NCLT's 2026 finding that the Committee of Creditors was dominated by "related and interested entities" accused of criminal misconduct supports the former reading.
Receivables. Implied receivables of roughly ₹430–480 Cr sat on the balance sheet from FY2016 to FY2019 against annual revenue of ₹19–27 Cr. The Sep 2020 quarter's ₹373 Cr expense line and the ₹308 Cr fall in "other assets" (₹424 Cr to ₹116 Cr) are consistent with a large write-off of these receivables.
Cash flow. FY2016's +₹114 Cr operating cash flow, matched by -₹139 Cr investing outflow (investments rose ₹140 Cr), suggests collections were redeployed into investments (possibly group entities) rather than used to repay debt. From FY2017, operations consumed cash every year, funded by small financing inflows (₹5–16 Cr).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products/services | Facilities |
|---|---|---|---|
Agri Business | Floriculture; welded wire mesh and wire products for the poultry industry (vendors classify the steel unit under agri given its poultry end-market) | Cut flowers; welded wire mesh (100 grades), barbed/razor wire inputs, chain-link fencing | Floriculture: Sirmour, HP; Steel/wire: Ropar, Punjab |
Pharma, Chemical & Minerals | Trading and marketing of pharmaceutical formulations; chemical and mineral trading | Branded formulations (Anemi-XT, Valcal-M, Gasease, IGTG Forte and others); traded chemicals/minerals | Pharma unit: Solan, HP |
Segment revenue (INR Cr, standalone)
| Segment revenue (INR Cr, standalone) | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Total revenue (INR Cr) | 27 | 27 | 14 |
Total revenue YoY growth (%) | 13 | 0 | -48 |
Results by Segment
| Segment results (INR Cr) | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Total operating profit before other income (INR Cr) | -10 | -53 | -51 |
Group Entities
| Entity | Relationship | Status | Source |
|---|---|---|---|
Alchemist Healthcare Limited | Subsidiary (per latest vendor profile) | — | MarketScreener |
Alchemist Foods Ltd | Wholly owned subsidiary acquired Feb 2009 (Republic of Chicken) | Current status not publicly disclosed | IIFL |
Alchemist Infra Realty Ltd | Group company (not a disclosed subsidiary) — subject of SEBI CIS order and ED attachment | Under PMLA proceedings | ED via media |
Alchemist Township India Ltd | Group company — CIRP from 25 Jan 2019; stayed by NCLT 10 Jun 2026 per Calcutta HC direction | Under CIRP (stayed) | IBBI; ATIL RP site |
Alchemist Holdings Ltd | Group company — CIRP admitted 4 Jun 2025 on petition of KDS Corporation Pvt Ltd | Under CIRP | IBBI |
Alchemist Capital Ltd | Group company — CIRP admitted 1 Aug 2025 (NCLT Chandigarh) | Under CIRP | IBBI |
Alchemist Corporation Ltd (BSE 531409) | Separately listed, formerly Haryana Fibres Ltd; group affiliation historically | Listed, trading | Screener.in; Pocketful |
Alchemist Hospitals / Ojas Hospital (Panchkula) | Group-linked hospitals; ₹127.33 Cr of shares held by Sorus Agritech attached by ED | Attached under PMLA | Moneylife |
“—” = not publicly disclosed.
Income Statement and Per-Share Data
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue (INR Cr) | 19 | 24 | 27 | 27 | 14 |
Total expenses (INR Cr) | 45 | 53 | 36 | 80 | 65 |
EBITDA / operating profit (INR Cr) | -26 | -29 | -10 | -53 | -51 |
Other income (INR Cr) | 19 | -69 | 3 | 1 | 0 |
Depreciation (INR Cr) | 9 | 8 | 8 | 7 | 7 |
Interest (INR Cr) | 3 | 2 | 2 | 1 | 1 |
EBIT derived as PBT plus interest (INR Cr) | -16 | -106 | -14 | -60 | -57 |
Pre-tax income (INR Cr) | -19 | -108 | -16 | -61 | -58 |
Net income (INR Cr) | -21 | -107 | -17 | -50 | -47 |
EPS basic (INR) | -15.40 | -79.06 | -12.47 | -36.61 | -34.46 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
EBITDA margin (%) | -136 | -122 | -36 | -199 | -354 |
EBIT margin derived (%) | -84 | -442 | -52 | -222 | -407 |
Net margin derived (%) | -111 | -446 | -63 | -185 | -336 |
Revenue YoY growth (%) | -92 | 26 | 13 | 0 | -48 |
Income Statement and Margin Analysis (%)
| Metric | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 386 | 396 | 411 | 522 | 667 | 827 | 252 |
EBITDA (INR Cr) | 32 | 32 | 15 | 13 | 16 | 12 | -32 |
EBITDA margin (%) | 8 | 8 | 3.5 | 2.6 | 2.4 | 1.5 | -13 |
Net income (INR Cr) | 14 | 16 | 8 | 16 | 16 | 17 | -20 |
EPS (INR) | 11.50 | 12.91 | 6.63 | 12.51 | 11.95 | 12.29 | -14.72 |
Borrowings (INR Cr) | 151 | 157 | 185 | 316 | 302 | 773 | 704 |
Debtor days | 16 | 16 | 15 | 12 | 4 | 168 | 659 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data (Quarterly)
| Metric (INR Cr, standalone) | Q1 FY2021 (Jun 2020) | Q2 FY2021 (Sep 2020) |
|---|---|---|
Revenue | 1 | 1 |
Expenses | 1 | 373 |
Other income | 0 | 124 |
Pre-tax income | -1 | -250 |
Net income | -2 | -186 |
EPS (INR) | -1.15 | -136.85 |
Balance Sheet and Working Capital (Days)
| Metric (INR Cr, standalone, 31 Mar) | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Equity share capital | 14 | 14 | 14 | 14 | 14 |
Reserves | 11 | -96 | -113 | -163 | -210 |
Total equity (net worth) | 25 | -82 | -99 | -149 | -196 |
Borrowings (total debt) | 727 | 740 | 752 | 763 | 767 |
Other liabilities | 173 | 178 | 170 | 161 | 161 |
Total liabilities and equity | 925 | 835 | 822 | 774 | 733 |
Fixed assets (net) | 174 | 162 | 154 | 147 | 140 |
Capital work in progress | 2 | 0 | 0 | 0 | 0 |
Investments | 244 | 171 | 169 | 169 | 169 |
Other assets (incl. receivables, inventory, cash) | 505 | 503 | 500 | 459 | 424 |
Implied trade receivables derived from debtor days | 476 | 476 | 479 | 430 | 368 |
Cash Flow
| Metric (INR Cr) | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Operating cash flow | 114 | -24 | -14 | -7 | -4 |
Investing cash flow | -139 | 9 | 4 | -3 | 0 |
Financing cash flow | 22 | 16 | 10 | 9 | 5 |
Net cash flow | -3 | 1 | 0 | -1 | 0 |
Free cash flow (per Screener) | 114 | -19 | -13 | -7 | -4 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
ROE on closing equity (%) | -84 | — | — | — | — |
ROA on closing assets (%) | -2.3 | -12.8 | -2.1 | -6.5 | -6.4 |
ROCE per Screener (%) | -2 | -5 | -2 | -9 | -10 |
Debt to equity (x) | 29.1 | — | — | — | — |
Interest coverage EBIT over interest (x) | -5.3 | -53.0 | -7.0 | -60.0 | -57.0 |
Asset turnover (x) | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
Debtor days | 9,151 | 7,232 | 6,471 | 5,807 | 9,597 |
Inventory days | 196 | 114 | 36 | 19 | 20 |
Payable days | 4,026 | 2,641 | 2,554 | 2,430 | 4,894 |
Cash conversion cycle (days) | 5,321 | 4,706 | 3,952 | 3,397 | 4,724 |
Geographic revenue (INR Cr)
| Geographic revenue (INR Cr) | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Total revenue (INR Cr) | 27 | 27 | 14 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last traded price | ₹3.01 (13 Dec 2021) | BSE; Screener.in |
Previous close before last trade | ₹2.87 | BSE |
52-week high / low (as of last trade) | ₹11.69 / ₹2.73 | BSE |
Market cap (full / free float) | ₹4.08 Cr / ₹2.66 Cr | BSE |
10-year price CAGR (to last trade) | -20% | Screener.in |
5-year price CAGR (to last trade) | -1% | Screener.in |
1-year and 3-year returns (to Oct 2026) | Not measurable; stock suspended since Dec 2021 | — |
Trading status | Suspended (BSE: non-payment of ALF dues); NSE series BZ | BSE; Screener.in |
Valuation Snapshot by Multiple
| Multiple | Value | Basis |
|---|---|---|
EV (derived) | ~768 (₹ Cr) | Market cap ₹4.08 Cr + borrowings ₹764 Cr (Sep 2020); cash not disclosed |
EV/Sales (derived) | ~128x | EV ~₹768 Cr / TTM revenue ₹6 Cr |
Dividend metric
| Dividend metric | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|---|---|---|---|---|---|
Dividend payout ratio (%) | 17 | 16 | 30 | 16 | 13 | 0 |
Implied DPS derived as EPS times payout (INR) | 1.96 | 2.07 | 1.99 | 2.00 | 1.55 | 0 |
Credit Ratings
| Agency | Rating | Date | Facilities |
|---|---|---|---|
CRISIL | D (Issuer Not Cooperating) | 27 Nov 2025 (reaffirmed; same rating 30 May 2022, 28 Jul 2023, 30 Sep 2024) | Cash credit ₹3.50 Cr; term loan ₹7.18 Cr; proposed long-term facility ₹21.82 Cr; total ₹32.5 Cr |
Moody's / S&P / Fitch | Not rated | — | — |
Analyst Conclusions
Management guidance and consensus
Management guidance: none published. Consensus estimates: none (no coverage). The company has filed no financial results for more than six years' worth of quarters since Sep 2020.
Bull case (low probability)
-
Asset backing for a court-supervised realisation. Fixed assets of ₹137 Cr and investments of ₹169 Cr (Sep 2020 book) could, if not confiscated, fund partial creditor and investor recovery under Calcutta HC supervision.
-
Liability shrinkage via write-backs. Q2 FY2021's ₹124 Cr other income suggests liabilities can be extinguished; if related-party debts (dominant in the CoC) are disallowed or subordinated, the effective debt burden could fall sharply.
-
Clean-slate restructuring. The recall of a fraudulent CIRP could open the door to a genuinely independent restructuring, preserving the listed shell's value for minority shareholders.
Bear case (high probability)
-
Equity is deeply out of the money. Liabilities of ~₹806 Cr (₹764 Cr borrowings + ₹42 Cr other liabilities) against ₹422 Cr of book assets at Sep 2020, before any further impairment.
-
PMLA primacy. The NCLT ruled that IBC cannot be used to legitimise proceeds of crime; assets traced to the CIS can be confiscated, leaving little for shareholders.
-
Delisting and disclosure collapse. No filings since 2020, unpaid listing fees and a non-cooperating rating status point toward compulsory delisting.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Outcome of NCLT hearing scheduled 5 Oct 2026 in ATIL CIRP | Indicates how group insolvencies will be handled after HC stay |
| Any appeal by Sai Tech Medicare or the RP against the 3 Feb 2026 recall at NCLAT | Could revive or permanently close the Alchemist Ltd CIRP |
| CBI, ED and SEBI status reports to Calcutta HC | Could establish fraud findings, offshore fund flows, and the role of Technology Parks Ltd |
| Special PMLA Court progress on ED complaints | Confiscation risk for company assets |
| BSE/NSE action on compulsory delisting | Determines whether minority shareholders retain any listed exit |
| Any filing of financial results for FY2021–FY2026 | Would reveal post-2020 asset and liability position |
| CRISIL annual review (due ~Nov 2026) | Confirms continued default status |
Analyst verdict
Alchemist Limited should be understood not as an investable company but as a legal estate. Its operating history divides cleanly into two eras. From FY2009 to FY2014 it was a growing, dividend-paying, low-margin trading and agri-processing business, peaking at ₹827 Cr of revenue. From FY2015 onward it became a shell: revenue collapsed to ₹19 Cr within two years, ~₹475 Cr of receivables stopped turning, borrowings froze at ~₹750 Cr with interest barely recognised, and net worth slid from positive ₹25 Cr to roughly negative ₹383 Cr by September 2020. The pattern — debt-funded receivables that never convert to cash, investments impaired shortly after being made, and liabilities owed largely to parties that do not charge commercial interest — is consistent with the fund-diversion narrative that the Enforcement Directorate has alleged across the Alchemist Group.
The February 2026 NCLT recall is the single most important fact for any stakeholder. By holding that the insolvency was engineered through collusion and that a related-party-dominated creditor committee cannot be allowed to clean assets of criminal taint, the tribunal effectively ranked investor restitution and PMLA confiscation ahead of corporate resolution. The Calcutta High Court has reinforced that stance, freezing group CIRPs and directing agencies to trace offshore flows.
For minority shareholders, the economic conclusion is stark: liabilities materially exceed assets even at stale book values, assets face confiscation risk, the stock has not traded since December 2021, and the company has not filed results in six years. Equity value is best regarded as nil, with option value only in improbable scenarios. For creditors, recoveries depend on court-supervised realisation and on how related-party claims are treated. For researchers, the company is a case study in governance failure and the limits of the IBC. Verdict: uninvestable; monitor only for legal outcomes and delisting action.
Source list (primary references used)
-
Screener.in — Alchemist Ltd standalone and consolidated financials, shareholding, announcements (data from BSE filings): https://www.screener.in/company/ALCHEM/
-
BSE — RP intimation, 18 Apr 2022; trading-window letter, 4 Jan 2021; stock quote/suspension status (BSE code 526707)
-
IBBI — Public announcement and order register for CIN L72200DL1988PLC192643; lists of creditors (19 Jan 2022; 29 Jul 2022); Alchemist Holdings and Alchemist Capital CIRP records
-
CRISIL Ratings — Alchemist Limited rating rationale, 27 Nov 2025
-
Moneylife — NCLT recall of Alchemist Ltd CIRP (5 Feb 2026); ED attachment of hospital shares
-
LiveLaw — NCLT recall reasoning (12 Feb 2026); Calcutta HC order coverage (20 Apr 2026); KD Singh bail (Apr 2021)
-
Tax Concept — ED statement on NCLT recall (Feb 2026)
-
ATIL Resolution Professional — Calcutta HC intimation (2 Apr 2026); update on proceedings (1 Jul 2026)
-
IIFL — Alchemist Ltd company summary (history and name changes)
-
NSE — Press release on share consolidation, 27 Jul 2007
-
Business Standard; BFSL/Vogue Stock — ISIN, incorporation date, registered office, peer data
-
Yahoo Finance; MarketScreener; Financial Modeling Prep — management, employees, segments, products, plant locations
-
Wikipedia — K. D. Singh (politician); Anglia Ruskin University honorary award citation
-
The Wire; The Quint; Deccan Herald; Millennium Post; Daily Pioneer; Indian Express (via IIIT JPMC archive) — ED investigations, arrest, attachments
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / notes | Year born | Reported pay (₹, latest available year) | Source |
|---|---|---|---|---|---|
Bikram Bhattacharya | CEO & Whole-Time Director | Tenure start not disclosed | 1953 | 2.78 million | Yahoo Finance |
Anop Singh Negi | Chief Financial Officer | Since 10 Jul 2019 | 1973 | 492,350 | Yahoo Finance; MarketScreener |
Divya Bajaj | Company Secretary & Compliance Officer | Resigned 6 Feb 2021 | — | 348,000 | Yahoo Finance; BSE |
Gaurav Arora | VP, Marketing & Sales | — | 1978 | — | Yahoo Finance |
Ajay Arora | VP, Steel & Floriculture | — | 1952 | — | Yahoo Finance |
Madhu Tara | AGM, HR & Administration | — | 1975 | — | Yahoo Finance |
Anjali Saxena | Head of HR | — | 1959 | — | Yahoo Finance |
Dr Inderjit Singh Virdi | MD, Alchemist Hospitals Ltd (group) | — | — | — | Yahoo Finance |
“—” = not publicly disclosed.
Board of Directors
| Person | Role | Notes | Source |
|---|---|---|---|
Dr Kanwar Deep Singh (b. 21 Aug 1961) | Founder; Chairman until 2012; thereafter Chairman Emeritus of the group | Rajya Sabha MP 2010–2020 (TMC from 2014); arrested by ED 12 Jan 2021; bailed Apr 2021. Has denied involvement and stated he was not a director/shareholder of the investigated CIS companies. | Wikipedia; LiveLaw; Moneylife |
Karan Deep Singh | Son of founder; chairs the Alchemist Group | Named in 2018 Kolkata Police case; beneficial owner of Sorus Agritech, whose ₹127.33 Cr hospital shareholdings were attached by ED | Wikipedia; Moneylife |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
10 Jul 2019 | Anop Singh Negi appointed CFO | Per MarketScreener |
6 Feb 2021 | CS Divya Bajaj resigns | Weeks after the founder's ED arrest |
30 Nov 2021 | Board suspended; IRP Chandra Prakash takes control | CIRP admission |
10 Feb 2022 | Gaurav Misra confirmed as RP | NCLT order |
3 Feb 2026 | RP appointment nullified | NCLT recall order |
Shareholding Trend
| Holder category (%) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 |
|---|---|---|---|---|---|
Promoters (%) | 34.97 | 34.94 | 34.94 | 34.94 | 34.94 |
FIIs (%) | 17.19 | 9.75 | 3.50 | 0.00 | 0.00 |
DIIs (%) | 3.79 | 2.48 | 2.49 | 2.48 | 1.51 |
Public (%) | 44.05 | 52.82 | 59.07 | 62.57 | 63.54 |
Number of shareholders | 8,347 | 8,591 | 8,708 | 8,640 | 10,223 |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors | Relative positioning of Alchemist |
|---|---|---|
Steel wire and welded mesh | Tata Steel (wires business), Usha Martin, Bansal Wire Industries, Rajratan Global Wire, numerous unorganised Punjab/Ludhiana mesh makers | Marginal; single plant at Ropar, sub-scale |
Poultry and processed chicken (historical) | Venky's (India), Godrej Agrovet (Real Good Chicken), Suguna Foods, Licious | Exited / dormant; Republic of Chicken no longer reported |
Pharma formulations (iron, calcium, nutraceutical) | Mankind Pharma, Alkem Laboratories, Macleods, Abbott India, numerous PCD/franchise players | Negligible share; small branded-generic portfolio |
Floriculture | Fragmented; listed historical peer Karuturi Global (itself collapsed); many unlisted growers in Bengaluru, Pune, Himachal | Negligible |
Chemical and mineral trading | Highly fragmented trading houses | Exited (trading collapsed FY2015–FY2016) |
Diversified classification peers (per exchange data) | 3M India, Balmer Lawrie, DCM Shriram Consolidated | Not comparable in scale |
Key Competitors
| Company | Market cap (INR Cr, per BFSL peer table) | Notes |
|---|---|---|
Alchemist Ltd | 4.08 | Last traded Dec 2021; suspended |
3M India | 38,053 | Diversified peer per exchange classification |
DCM Shriram Consolidated | 18,038 | Diversified peer |
Balmer Lawrie | 2,873 | Diversified peer |
Recent Developments
The company itself has made no exchange disclosures in this period.
Discrepancy note: LiveLaw's 20 Apr 2026 report refers to the "NCLT Kolkata's recall order," whereas the IBBI register and Moneylife identify the recall order as passed by NCLT New Delhi Bench IV. The IBBI record is treated as authoritative.



